Neuren Pharmaceutica (NURPF) 0.1000 $NURPF
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2014
M2 - Wed Jun 25, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5b6wvm/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Neuren Pharmaceuticals Limited - Paladin Labs Inc. - Protemix Corporation Limited - Relevare Pharmaceuticals Ltd. - Regenesance BV For more information visit http://www.researchandmarkets.com/research/5b6wvm/peripheral
Fragile X Syndrome - Pipeline Review, H2 2013
M2 - Thu Jan 23, 8:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/gmtj7c/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H2 2013" report to their offering. 'Fragile X Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Scope - A snapshot of the global therapeutic scenario for Fragile X Syndrome. - A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fragile X Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Companies Mentioned F. Hoffmann-La Roche Ltd. Novartis AG Paratek Pharmaceuticals, Inc. Neuren Pharmaceuticals Limited Cortex Pharmaceuticals, Inc. Seaside Therapeutics, LLC Snowdon Inc. Marinus Pharmaceuticals, Inc. Nexgenix Pharmaceuticals, LLC aFraxis Inc. Alcobra Ltd Sage Therapeutics Confluence Pharmaceuticals LLC SMaRT Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/gmtj7c/fragile_x About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dementia - Pipeline Review, H2 2012: Plan Mergers and Acquisitions Effectively By Identifying Players of the Most Promising Pipeline
M2 - Mon Jan 14, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/jbsd8v/dementia) has announced the addition of Global Markets Direct's new report "Dementia - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Dementia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia. Dementia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Dementia. - Coverage of products
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2014
M2 - Wed Jun 25, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5b6wvm/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Neuren Pharmaceuticals Limited - Paladin Labs Inc. - Protemix Corporation Limited - Relevare Pharmaceuticals Ltd. - Regenesance BV For more information visit http://www.researchandmarkets.com/research/5b6wvm/peripheral
Fragile X Syndrome - Pipeline Review, H2 2013
M2 - Thu Jan 23, 8:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/gmtj7c/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H2 2013" report to their offering. 'Fragile X Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Scope - A snapshot of the global therapeutic scenario for Fragile X Syndrome. - A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fragile X Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Companies Mentioned F. Hoffmann-La Roche Ltd. Novartis AG Paratek Pharmaceuticals, Inc. Neuren Pharmaceuticals Limited Cortex Pharmaceuticals, Inc. Seaside Therapeutics, LLC Snowdon Inc. Marinus Pharmaceuticals, Inc. Nexgenix Pharmaceuticals, LLC aFraxis Inc. Alcobra Ltd Sage Therapeutics Confluence Pharmaceuticals LLC SMaRT Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/gmtj7c/fragile_x About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dementia - Pipeline Review, H2 2012: Plan Mergers and Acquisitions Effectively By Identifying Players of the Most Promising Pipeline
M2 - Mon Jan 14, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/jbsd8v/dementia) has announced the addition of Global Markets Direct's new report "Dementia - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Dementia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia. Dementia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Dementia. - Coverage of products
